One-year outcomes in lung transplant recipients with NAFLD
| Outcome (within 1 year post-transplantation unless otherwise specified) | Patients with NAFLD | Patients without NAFLD | p-value |
| ICU-free days within 10 days post-transplant (median, IQR) | 5.0 (2.0–6.0) | 3.0 (0–6.0) | 0.27 |
| Hospital-free days within 30 days post-transplant (median, IQR) | 16.0 (10.5–19.5) | 12.0 (0–18.0) | 0.03 |
| Transfusion (within 3 days post-transplant) | |||
| Packed red blood cells >2 units | 11/40 (28) | 47/110 (43) | 0.13 |
| Fresh frozen plasma >2 units | 17/40 (43) | 39/110 (36) | 0.45 |
| Platelets (any) | 21/40 (53) | 46/110 (42) | 0.27 |
| Cryoprecipitate (any) | 10/40 (25) | 19/110 (17) | 0.35 |
| Atrial fibrillation during index hospitalisation | 21/40 (53) | 46/108 (42) | 0.35 |
| Delirium during index hospitalisation | 16/40 (40) | 55/108 (51) | 0.27 |
| Daily tacrolimus dose required to maintain a goal trough of 8–12 ng/mL prior to index hospitalisation discharge mg (median, IQR) | 6.0 (4.0–8.5) | 8.0 (5.0–10.0) | 0.66 |
| Venous thromboembolism within initial 12 months# | 16/38 (42) | 44/103 (43) | 1.00 |
| Acute cellular rejection event (any grade, within initial 12 months)# | 18/38 (47) | 41/102 40) | 0.45 |
| Need for insulin at time of discharge from index hospitalisation | 29/40 (73) | 70/104 (67) | 0.77 |
| Need for insulin within initial 12 months# | 16/38 (42) | 31/102 (30) | 0.23 |
| % decline of pre-transplant glomerular filtration rate (CKD-EPI) at 12 months# | 48 (33–57) | 58 (42–68) | 0.03 |
| Unplanned re-hospitalisations within initial 12 months post-transplant# | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 0.43 |
| CMV viraemia (viral load >137 copies) incidence within initial 12 months post-transplant | 6/40 (15) | 19/110 (17) | 0.74 |
| Hospitalisation for infection during initial 12 months post-transplant# | 20/38 (53) | 43/102 (42) | 0.34 |
Data expressed as n (%) unless otherwise indicated. NAFLD: non-alcoholic fatty liver disease; ICU: intensive care unit; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CMV: cytomegalovirus. #: for those surviving to the given outcome.